These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
813 related items for PubMed ID: 37474112
1. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals. Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, Tu YK. Eur J Endocrinol; 2023 Jul 20; 189(1):S17-S25. PubMed ID: 37474112 [Abstract] [Full Text] [Related]
2. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, Rangaswami J. Cardiorenal Med; 2020 Jul 20; 10(1):1-10. PubMed ID: 31743918 [Abstract] [Full Text] [Related]
3. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Lin DS, Lee JK, Hung CS, Chen WJ. Diabetologia; 2021 Dec 20; 64(12):2676-2686. PubMed ID: 34536085 [Abstract] [Full Text] [Related]
11. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Zhao Z, Jin P, Zhang Y, Hu X, Tian C, Liu D. Front Cardiovasc Med; 2022 Jun 04; 9():826684. PubMed ID: 35557542 [Abstract] [Full Text] [Related]
12. Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis. Kovil R, Chawla M, Shah T, Sahoo A, Makkar B, Kesavadev J, Seshadri K, Tiwaskar M, Rajput R, Phatak S, Majumdar S, Gupta S. J Assoc Physicians India; 2022 Aug 04; 70(8):11-12. PubMed ID: 36082726 [Abstract] [Full Text] [Related]
17. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis. Diallo A, Carlos-Bolumbu M, Galtier F. Acta Diabetol; 2023 Dec 04; 60(12):1651-1662. PubMed ID: 37439858 [Abstract] [Full Text] [Related]